Aevi Genomic Medicine, Inc.(NASDAQ : GNMX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
Loading GNMX News...
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||0.03%||67.51||1.0%||$577.68m|
|REGN||Regeneron Pharmaceuticals, Inc.||2.19%||373.00||2.1%||$320.06m|
|KITE||Kite Pharma, Inc.||3.14%||76.84||18.8%||$224.79m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.83%||119.26||1.6%||$202.56m|
|ESPR||Esperion Therapeutics, Inc.||-3.61%||38.94||18.7%||$173.60m|
|AUPH||Aurinia Pharmaceuticals Inc.||-4.41%||8.02||6.3%||$150.20m|
|CLVS||Clovis Oncology, Inc.||2.61%||70.32||17.5%||$142.57m|
|VRTX||Vertex Pharmaceuticals Incorporated||1.04%||89.98||2.2%||$135.11m|
Aevi Genomic Medicine, Inc. is a medical technology company, which focuses on finding treatments for rare and orphan diseases, with a particular focus on pediatrics, following a genomics medicine strategy. Its Transduced Autologous Restorative Gene Therapy platform is designed to provide sustained protein and peptide therapies to treat a range of chronic diseases and conditions. The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.